Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
DURHAM, N.C., Nov. 09, 2016 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle Berrey, M.D., M.P.H, President and Chief Executive Officer of Chimerix, will present a corporate overview at the following upcoming conferences:
- Stifel 2016 Healthcare Conference at 1:30 p.m. ET on Tuesday, November 15, 2016 at the Lotte New York Palace Hotel in New York
- 28th Annual Piper Jaffray Healthcare Conference at 11:30 a.m. ET on Wednesday, November 30, 2016 at the Lotte New York Palace Hotel in New York
A live audio webcast of each presentation will be available on the Investor Relations section of Chimerix’s website at www.chimerix.com, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel antivirals in areas of high unmet medical need. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage compounds. Chimerix is also advancing a clinical candidate for norovirus infection, CMX521. For further information, please visit Chimerix's website www.chimerix.com.
CONTACT: Investor Relations: [email protected] or Will O’Connor Stern Investor Relations [email protected] 212-362-1200 Media: Becky Vonsiatsky W2O Group [email protected] 413-478-2003
